For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Hosptial infection is categorized based on infection types into the following segments: blood stream infection (BSI) testing, urinary tract infection (UTI) testing, methicilin-resistant staphylococcus aureus (MRSA) testing, pneumonia testing, surgical site infection (SSI) testing & others infections such as cardio vascular infection, gastrointestinal infections & respiratory infections.
LPI (LP Information)' newest research report, the "Hospital Acquired Disease Testing Industry Forecast" looks at past sales and reviews total world Hospital Acquired Disease Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Hospital Acquired Disease Testing sales for 2023 through 2029. With Hospital Acquired Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hospital Acquired Disease Testing industry.
This Insight Report provides a comprehensive analysis of the global Hospital Acquired Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hospital Acquired Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hospital Acquired Disease Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hospital Acquired Disease Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hospital Acquired Disease Testing.
The global Hospital Acquired Disease Testing market size is projected to grow from US$ 443.3 million in 2022 to US$ 965.7 million in 2029; it is expected to grow at a CAGR of 11.8% from 2023 to 2029.
One of the key factors driving industry growth is the rising geriatric population base. Advancing age of the geriatric population makes them more vulnerable and prone to diseases, thus increasing the demand for diagnosis. Other aspects supporting industry growth are growing demand of HAI diagnostics from middle and low-income countries such as India and Brazil, development of technologically advanced diagnostic products, rising awareness among healthcare workers, and initiatives taken by governments to counter the prevalence of HAIs. However, decreasing prevalence of nosocomial infections in the developed countries owing to improved healthcare infrastructure and rising awareness are expected to restrict industry growth.
This report presents a comprehensive overview, market shares, and growth opportunities of Hospital Acquired Disease Testing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Instrument and Reagents
- Consumables
Segmentation by application
- Disease Testing
- Drug-Resistance Testing
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Life technologies
- Diatherix laboratories
- Qiagen GmbH
- Meridian Biosciences
- Nordion
- Roche
- Cantel Medical Corporation
- Cepheid